BFC Planning’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.5K Hold
178
– – ﹤0.01% 2308
2026
Q2
$14.5K Hold
178
– – ﹤0.01% 2166
2026
Q1
$12.1K Sell
178
-197
-53% -$14K ﹤0.01% 1946
2025
Q4
$28.5K Buy
375
+14
+4% +$1.02K ﹤0.01% 1591
2025
Q3
$22.2K Buy
+361
New +$18.8K ﹤0.01% 1524
2025
Q1
– Sell
-75
Closed -$3.39K – 2727
2024
Q4
$3.39K Buy
+75
New +$3.21K ﹤0.01% 2129

Other funds holding PTCT

BFC Planning's PTCT Position: Q3 2026 in Review

BFC Planning held its PTC Therapeutics (PTCT) position steady in Q3 2026 at 178 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2308.

BFC Planning first reported a position in PTCT in Q4 2024 and has held it in 6 quarters since. The position peaked at $28.5K in Q4 2025. 281 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • BFC Planning held 178 shares of PTC Therapeutics worth $11.5K as of Q3 2026.
  • BFC Planning left its PTC Therapeutics share count unchanged in Q3 2026.
  • PTC Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2308 holding.
  • BFC Planning first reported a position in PTC Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BFC Planning's PTC Therapeutics position peaked at $28.5K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.